… Two GC patients achieved durable response after pseudo-progression. The most common
treatment-related adverse events in the atezolizumab monotherapy group were fatigue, …

… in patients with advanced melanoma who discontinued … 细胞癌患者中，派姆单抗（Pembrolizumab）显示
出抗肿瘤活性和良好的安全… in patients with metastatic castration-resistant prostate …

… Pembrolizumab is effective for drug‐resistant gestational trophoblastic neoplasia[J… patients
responding to anti‐PD‐1/PD‐L1 therapy and disease outcome upon treatment discontinuation…

… Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in
a patient with metastatic melanoma[J]. BMJ Case Rep, 2016, pii: bcr2016217454. …

… The reasons for treatment discontinuation were adverse events in 10, 27, and 24% of the
patients … Everolimus is the first targeted agent to show robust anti-tumour activityacross a broad …

… are the most common irAEs leading to discontinuation of ICIs. Timely prevention and
management of immune-related colitis are required to ensure that cancer patients can benefit from …

… 8例患者达到完全缓解(complete response, CR),疾病控制率(… 维持治疗停药时间 (time to
discontinuation,TTD),是基于美 国… alone in platinum-resistant or platinumrefractory ovarian cancer (…

… This may be related to treatment interruption. For patients with high-level irAEs, they
should be standardized treat according to the guidelines and hormones and even immuno-…

… pembrolizumab)治疗的NSCLC患者客观 缓解率(overall response rate,ORR),持续临 床获益
(durable … ,高TMB组的治疗终止时 间(time to treatment discontinuation,TTD)和 OS显著短于中,低…

… 3度及以上不良反应发生率为81%，72%的患者疗效评估为疾病稳定（stable disease, SD）、完全
缓解（complete response, CR）或部分缓解（partial response, PR），mPFS为2.2个月，患者均…